Pneumococcal 20-Valent Conjugate Vaccine

Introduction Overview

Generic Name

Pneumococcal 20-valent conjugate vaccine

Brand Name

Prevnar 20

Dosage Form

Intramuscular injection

Drug Class

Bacterial vaccines

Pharmacokinetics

Pharmacokinetics of vaccines like Prevnar 20 differ significantly from small molecule drugs as they involve immunologic rather than classical ADME (absorption, distribution, metabolism, elimination) pathways. However, key aspects of its pharmacokinetics can be discussed in the context of vaccine administration and immune response development.

Absorption: Upon intramuscular injection, the vaccine's polysaccharide-protein conjugates are taken up by local antigen-presenting cells (APCs) such as dendritic cells and macrophages. The physical formulation allows slow release and processing of the pneumococcal polysaccharides combined with CRM197 carrier protein, facilitating effective antigen presentation. The absorption into systemic circulation is limited as the vaccine aims to remain localized to lymphoid tissues to generate an immune response. The intramuscular site allows optimal delivery into the muscle tissue with rich blood supply to support immune cell recruitment and activation.

Distribution: Once taken up by APCs, these cells migrate to regional lymph nodes where they present processed antigen to naive T and B lymphocytes, triggering adaptive immunity. The conjugate vaccine components do not exhibit systemic distribution akin to drugs but are confined to the immune system compartments where immunologic processing occurs. Vaccine particles are not distributed like drugs but function as immunogens activating systemic humoral and cellular immunity.

Metabolism: The vaccine components are metabolized via lysosomal processing within APCs. The polysaccharide antigens are processed and displayed on MHC class II molecules along with peptide fragments of the carrier protein to T-helper cells, stimulating B cell activation and antibody production. The CRM197 carrier protein, a non-toxic mutant of diphtheria toxin, is degraded intracellularly to peptides to facilitate T cell help. There is no classical hepatic metabolism; instead, enzymatic breakdown within immune cells occurs.

Elimination: Vaccine antigens and their fragments are eliminated primarily via phagocytosis and enzymatic degradation within immune cells. The antibodies produced as a result of vaccination circulate in the bloodstream providing protective immunity. Any residual vaccine components at the injection site or in lymphoid tissues are cleared by immune cell-mediated processes over days to weeks. No renal clearance or biliary excretion occurs for vaccine components. The immune response's durability depends on memory cell formation rather than pharmacokinetic clearance.

Dosage Forms

Available Dosage Forms:

Prevnar 20 is supplied as a 0.5 mL suspension in a single-dose pre-filled syringe intended for intramuscular injection. There are no oral or other formulations available. The suspension must be well mixed prior to administration to ensure even distribution of the vaccine components.

Dosages for Adults and Adolescents:

- Adults and individuals aged 18 years and older receive a single 0.5 mL intramuscular injection dose of Prevnar 20 for the prevention of pneumococcal disease and pneumonia caused by 20 pneumococcal serotypes.

Specific Patient Populations:

- Infants and Children (6 weeks through 5 years): The vaccine is administered as a four-dose series intramuscularly at approximately 2 months, 4 months, 6 months, and a booster at 12 through 15 months of age.
- Premature Infants: Caution is advised due to the risk of apnea; vaccination timing should be individualized considering medical status.
- Adults 60 years and older and at-risk populations: Single dose recommended; can be given concomitantly with other vaccines as per immunization schedule.

Clinical Guidelines:

- The vaccine should be stored refrigerated at 2 ºC to 8 ºC and not frozen.
- Intramuscular injection is recommended into the deltoid muscle in adults or anterolateral thigh in infants and young children.
- The vaccine should be thoroughly mixed by inversion before administration.
- No dosage adjustment is required based on age beyond the dosing schedule, renal, or hepatic impairment as it is a vaccine.
- Immunization schedules may vary slightly depending on national guidelines and patient risk factors.

Mechanism Of Action

Prevnar 20 is a pneumococcal conjugate vaccine designed to induce active immunity against 20 serotypes of Streptococcus pneumoniae, a major cause of invasive pneumococcal disease including pneumonia, meningitis, bacteremia, and otitis media.

The vaccine contains purified capsular polysaccharides from 20 pneumococcal serotypes conjugated covalently to CRM197, a non-toxic variant of diphtheria toxin that acts as a carrier protein. The conjugation enhances immunogenicity, especially in infants and young children who typically respond poorly to polysaccharide antigens alone.

Upon intramuscular injection, the polysaccharide-protein conjugates are taken up by antigen-presenting cells, which process the CRM197 protein into peptide fragments that are presented on MHC class II molecules. This presentation elicits a helper T-cell response that is crucial for stimulating B cells to produce high-affinity, serotype-specific IgG antibodies against the pneumococcal polysaccharides.

This T-cell-dependent pathway promotes immunological memory, enabling the immune system to mount a faster and stronger response upon subsequent exposure to pneumococci. The vaccine-generated antibodies opsonize pneumococcal bacteria, enhancing phagocytosis and clearance by immune cells, thereby preventing colonization and invasive infection.

Compared to older pneumococcal polysaccharide vaccines, Prevnar 20’s conjugate formulation allows effective protection in infants as young as six weeks and yields longer-lasting immunity. Clinical studies demonstrate that Prevnar 20 elicits robust antibody responses and mucosal immunity to a broader range of pneumococcal serotypes than its predecessor Prevnar 13, translating to expanded protection across multiple strains prevalent in the community.

In summary, Prevnar 20’s mechanism involves conjugate vaccine technology to harness the body's adaptive immunity, generating serotype-specific antibodies that neutralize and facilitate clearance of pneumococci, thereby preventing pneumococcal diseases.

Pharmacological Actions

Active immunization against Streptococcus pneumoniae serotypes causing invasive pneumococcal disease.
Induces T cell-dependent immune response via CRM197 carrier protein facilitating antibody production.
Generates serotype-specific IgG antibodies leading to opsonization and phagocytosis of pneumococcal bacteria.
Provides immunological memory for long-lasting protection against pneumococcal infections.
Prevention of pneumococcal pneumonia, bacteremia, meningitis, otitis media, and sinusitis.
Designed to protect infants, children, and adults including those with immune vulnerabilities.
Broader serotype coverage than previous pneumococcal conjugate vaccines (e.g., Prevnar 13).
Stimulates mucosal immunity reducing bacterial colonization in nasopharynx.
Enhances clearance of antibiotic-resistant pneumococcal strains through immune mechanisms.
Does not treat active infection but primes immune defenses for future exposure.

Therapeutic Or Clinical Uses

Prevention of invasive pneumococcal disease caused by 20 serotypes of Streptococcus pneumoniae in individuals 6 weeks and older.
Protection against pneumococcal pneumonia in adults aged 18 years and older.
Prevention of otitis media (ear infections) caused by specific pneumococcal serotypes in children aged 6 weeks through 5 years.
Immunization of infants and toddlers in a four-dose series for early protection against pneumococcal diseases.
Vaccination of adults and elderly populations at risk for pneumococcal infections and complications.
Part of recommended immunization schedules for prevention of pneumococcal diseases globally.
Use in immunocompromised individuals to reduce risk of serious bacterial infections.
Supplemental protection to existing pneumococcal vaccines with expanded serotype coverage.
Reduction in morbidity and mortality associated with pneumococcal infections.
Prevention of complications related to pneumococcal diseases such as meningitis and bacteremia.

Side Or Adverse Effects

Common injection site reactions including pain, redness, and swelling occurring in more than 10% of recipients.
Irritability and drowsiness frequently observed in infants and young children following vaccination.
Decreased appetite and fever reported in pediatric populations, especially after multiple doses.
Muscle pain, tiredness, and headache commonly reported in adults receiving the vaccine.
Joint pain observed in adults and elderly individuals post-vaccination.
Serious side effects such as high fever (≥102°F), seizures, or severe injection site irritation are rare but require immediate medical attention.
Allergic reactions including anaphylaxis, hives, swelling of the face, lips, tongue, or throat necessitate emergent care.
Apnea has been reported in some premature infants after vaccination; careful monitoring recommended.
Possible severe vomiting, diarrhea, or abdominal pain following vaccination reported in rare cases.
Transient systemic symptoms generally resolve without intervention.
No evidence of interference with concomitantly administered vaccines upon proper scheduling.
Local adverse events typically subside within a few days following vaccination.
Adverse reactions are less common and generally milder in older children and adults compared to infants.
Rare occurrences of neurological events have not been definitively linked to vaccination but are monitored.
Post-marketing surveillance continues to assess long-term safety and adverse event incidence.

Precautions

Do not administer Prevnar 20 to patients with a known severe allergic reaction to any pneumococcal vaccine or diphtheria toxoid-containing vaccine.
Use caution when vaccinating individuals with bleeding disorders or on anticoagulant therapy due to risk of bleeding at injection site.
Consider infant's medical status, especially in premature infants, due to observed apnea post-vaccination.
Delay vaccination if recipient has moderate or severe acute illness until recovery to prevent confounding adverse reactions.
Inform healthcare provider about immunosuppressive conditions or therapies prior to vaccination as response may be diminished.
Report history of previous vaccine reactions to provider before administration of Prevnar 20.
Monitor individuals with a history of allergies or asthma closely after vaccination for potential adverse reactions.
Ensure appropriate scheduling with other routine immunizations to maximize immune response and minimize adverse events.
Vaccination should be performed by trained healthcare providers with emergency treatments available.
Pregnant or breastfeeding women should inform their provider; limited safety data available but vaccination is generally considered safe.
Counsel patients regarding common side effects and the importance of completing the vaccination series in children.
Advise patients that vaccine efficacy may be reduced if immunocompromised.
Use caution in patients with active infections; vaccination should generally wait until resolution.
Pregnancy category is not assigned, but benefits versus risks should be evaluated in pregnant women.
Maintain proper vaccine storage to preserve efficacy and minimize risks associated with improper administration.

Warnings

Warning of apnea risk following vaccination in some premature infants; individual assessment required before administration.
Do not provide booster vaccinations to individuals who have experienced life-threatening allergic reactions to a prior dose of Prevnar 20.
Emergency medical help should be sought immediately if signs of severe allergic reaction occur, such as hives, difficulty breathing, or swelling of face or throat.
Vaccination should be postponed in persons experiencing moderate or severe acute illness to reduce risk of adverse reactions.
Cumulative storage and handling temperature excursions must be controlled to prevent vaccine degradation.
Use with caution in individuals with known hypersensitivity to vaccine components including aluminum phosphate adjuvant.
Apnea risk warrants monitoring premature infants post-vaccination in appropriate clinical settings.
Ensure vaccination sites are prepared for management of anaphylaxis or other severe adverse events.
Limited data on use during pregnancy; weigh potential benefits against theoretical risks before administration.
Do not administer if vaccine has been frozen or shows compromised integrity.
Inform patients that vaccination does not treat active infections and does not guarantee absolute protection.
Avoid unnecessary repeat doses; follow recommended immunization schedules strictly.
Vaccination providers should report serious adverse events to appropriate health authorities for ongoing safety monitoring.
Immunization programs should incorporate education about risks, benefits, and post-vaccination expectations.
Pooled safety data indicate serious adverse events are very rare but possible; vigilance required.

Contraindication

Known severe allergic reaction or anaphylaxis to any component of Prevnar 20 including diphtheria CRM197 protein.
History of life-threatening allergic reaction to any prior pneumococcal conjugate vaccine dose.
Hypersensitivity to neomycin, polymyxin B, or other vaccine excipients that may be present in trace amounts.
Do not vaccinate during moderate or severe acute illness until condition improves.
Individuals with uncontrolled bleeding disorders where intramuscular injections pose heightened risk.
Known allergy to aluminum phosphate or polysorbate 80 contained in the vaccine formulation.
Severe immunodeficiency where vaccine response is unlikely or could be harmful (consult specialist).
Do not administer if vaccine storage conditions have been violated, potentially destroying vaccine potency.
No contraindications related to age within indicated populations; infants from 6 weeks old eligible.
History of Guillain-Barré syndrome temporally associated with prior vaccination should be reviewed prior to administration.
Pregnancy or breastfeeding is not a strict contraindication but decision should be individualized.
Any prior serious adverse event related to vaccine warrant consultation before administration.
Avoid concurrent administration with other vaccines if specific contraindications exist for those vaccines.
Patients with unresolved or acute febrile illness should defer vaccination.
Contraindications also include any integration with other unapproved or experimental vaccines in clinical settings.

Drug Interactions

Prevnar 20 can be administered concomitantly with other routine vaccines such as diphtheria, tetanus, pertussis, hepatitis, and varicella without interference of immune response.
Concurrent use with immunosuppressive drugs (e.g., corticosteroids, chemotherapy agents) may reduce vaccine efficacy.
Caution with other vaccines containing diphtheria toxoid to avoid overlapping immune responses or increased reactogenicity.
No significant interactions reported with over-the-counter medications, vitamins, or herbal supplements.
Recent or concurrent administration of immunosuppressants may diminish antibody response to the vaccine.
No known pharmacokinetic drug interactions since vaccine acts via immunologic mechanisms.
Vaccination providers should evaluate all recent vaccines to avoid scheduling conflicts or reduced immunogenicity.
Agents that suppress or modulate immune function, such as biologics for autoimmune diseases, may impair vaccine response.
No contraindications or interactions noted when administered with pneumococcal polysaccharide vaccines but appropriate timing is recommended.
No interactions reported with common antibiotics or antiviral agents.
Interaction with anticoagulants or antiplatelet drugs may increase risk of injection site bleeding.
Monitor patients on immunomodulating therapies closely for immune response adequacy post-vaccination.
Clinical judgment required when co-administering with live vaccines as per immunization guidelines.
No special dose adjustments necessary based on other medications but timing of immunizations may need coordination.
Patients should inform providers of all medications and supplements prior to vaccination for optimal care.

Preparations Of The Drug

Supplied as a sterile, preservative-free suspension in a single-dose pre-filled syringe containing 0.5 mL per dose.
Each dose contains approximately 2.2 μg of each of 19 S. pneumoniae serotype saccharides and 4.4 μg of 6B saccharide.
Contains 51 μg CRM197 carrier protein per dose, which is a non-toxic diphtheria protein derivative enhancing immunogenicity.
Excipients include polysorbate 80, succinate buffer, sodium chloride, and aluminum phosphate as an adjuvant (125 μg aluminum).
Storage recommended under refrigeration at 2 ºC to 8 ºC with protection from freezing; do not shake vigorously.
Prior to administration, the vaccine must be resuspended by inverting the syringe gently multiple times until a homogeneous white suspension is observed.
Appearance after resuspension is a white, cloudy suspension suitable for intramuscular injection.
Manufactured by Wyeth Pharmaceuticals LLC, Pfizer Inc. subsidiary, ensuring GMP-compliant production and quality standards.
The vaccine is provided with sterile needles or requires separate administration sets as per clinical setting protocols.
Packaged in individual syringes to reduce contamination risk and enable convenient single-dose usage.
No preservatives are included; therefore, single-use only and unused portions must be discarded.
The aluminum phosphate adjuvant serves to enhance immune response by increasing antigen presentation.
Polysorbate 80 acts as a stabilizer to maintain the integrity and potency of vaccine components.
The vaccine is free from thimerosal or mercury-containing preservatives, suitable for pediatric immunization.
Disposal of used syringes must follow biohazard regulations to prevent needle-stick injuries and contamination.